Cancer clinical trials in the region Île-de-France

596 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 2 Lymphoma #NCT06558604 #2023-506706-40-00

[GLOASIS] Étude de phase II évaluant le GLOFITAMAB en association avec le VENETOCLAX plus le ZANUBRUTINIB ou le VENETOCLAX seul chez des sujets atteints d'un lymphome à cellules du manteau à haut risque non traité ou récidivant/réfractaire - Cohorte B

B cell lymphoma Mantel cell lymphoma Early (stage I and II) Disseminated (stage III and IV) None > 60 ml/min 50-60 ml/min 30-50 ml/min 1 2 3 or more Targeted therapy

Bispecific T-cell engager antibodies

13 recruiting sites

The Lymphoma Academic Research Organisation (LYSARC)

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04602377 #2024-515310-40-01

Ajout de pembrolizumab à la chimiothérapie standard chez les patients atteints de cancer de l'ovaire à petites cellules de type hypercalcémique

Other ovarian cancer Localized Locally Advanced Metastatic None Systemic Treatment-Naive Systemic Treatment-Naive

Immunotherapy Chemotherapy Immunotherapy Chemotherapy

6 recruiting sites

ARCAGY/ GINECO GROUP

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05872204

Abémaciclib et létrozole chez les patientes atteintes d'un cancer de l'ovaire rare à récepteurs d'œstrogènes positifs

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Other ovarian cancer Serous low grade carcinoma (LGSOC) Endometrioid carcinoma Stromal cells and sex cords tumor HR Positive Locally Advanced Metastatic 1 2 3 or more Chemotherapy Hormone therapy

Systemic Treatment-Naive

6 recruiting sites

Universitaire Ziekenhuizen KU Leuven

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06690775 #2024-517190-24-00

CATALINA-2 : Une étude clinique du TORL-1-23 dans le cancer de l'ovaire résistant au platine.

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Locally Advanced Metastatic Other mutation 1 2 3 or more Recurrence within 6 months after platinum-based tr... Chemotherapy

Systemic Treatment-Naive

3 recruiting sites

TORL Biotherapeutics, LLC

Phase 2 Liver and bile duct cancer #NCT06904170 #2024-514912-28-00

[ALICE] Durvalumab et trémélimumab avec ou sans perfusion intra-artérielle hépatique de chimiothérapie dans le carcinome hépatocellulaire

Hepatocellular carcinoma Unhealthy A None Systemic Treatment-Naive Systemic Treatment-Naive

Transarterial chemoembolization

5 recruiting sites

UNICANCER

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06833073 #2024-517335-46-00

[INTerpath-011] Étude clinique de l'INTISMERAN AUTOGENE (V940) et du BCG chez les personnes atteintes d'un cancer de la vessie

Non-invasive bladder cancer Localized None 1 Surgery

5 recruiting sites

Merck Sharp & Dohme LLC

Phase 2 Lung cancer #NCT06712316 #2024-515764-31-00

Sécurité, efficacité et pharmacocinétique du BNT327 en association avec la chimiothérapie et d'autres agents expérimentaux pour le cancer du poumon

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic None Systemic Treatment-Naive

ALK EGFR Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies

10 recruiting sites

BioNTech SE

Phase 2 Lung cancer #NCT07001618

[IMMUNOLIFE2] Microbiothérapie orale par pool fécal (MaaT033) concomitante au cemiplimab versus le traitement de choix de l'investigateur chez les patients atteints d'un cancer du poumon non à petites cellules avancé présentant une résistance au traitement due à l'absorption d'antibiotiques

NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Locally Advanced Metastatic 1 2 3 or more Immunotherapy

Systemic Treatment-Naive

3 recruiting sites

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Lymphoma #NCT05283720 #2023-505347-38-00

Etude de l'innocuité et la tolérabilité de l'EPCORITAMAB en association avec des agents antinéoplasiques chez les participants adultes atteints d'un lymphome non hodgkinien - Bras 1 à 4

B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma None 1 2 3 or more

Bispecific T-cell engager antibodies

8 recruiting sites

Abbvie

Phase 2 Breast cancer #NCT04965766 #2023-505923-30-00

[ICARUS-BREAST] Étude du PATRITUMAB DERUXTECAN (U3-1402) dans le cancer du sein localement avancé ou métastatique inopérable

HER2 Negative HR Positive Locally Advanced Metastatic Chemotherapy Targeted therapy Hormone therapy

10 recruiting sites

Gustave Roussy, Campus du cancer, Grand Paris